321 related articles for article (PubMed ID: 30095362)
1. Immunogenicity of a Candidate Ebola Hemorrhagic Fever Vaccine in Mice Based on Controlled In Vitro Expression of Ebolavirus Glycoprotein.
Kumar D; Gauthami S; Uma M; Nagalekshmi K; Rao PP; Basu A; Ella KM; Hegde NR
Viral Immunol; 2018 Sep; 31(7):500-512. PubMed ID: 30095362
[TBL] [Abstract][Full Text] [Related]
2. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
3. An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates.
Wu S; Kroeker A; Wong G; He S; Hou L; Audet J; Wei H; Zhang Z; Fernando L; Soule G; Tran K; Bi S; Zhu T; Yu X; Chen W; Qiu X
J Infect Dis; 2016 Oct; 214(suppl 3):S326-S332. PubMed ID: 27493239
[TBL] [Abstract][Full Text] [Related]
4. Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.
Lingemann M; Liu X; Surman S; Liang B; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
J Virol; 2017 May; 91(10):. PubMed ID: 28250127
[TBL] [Abstract][Full Text] [Related]
5. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
[TBL] [Abstract][Full Text] [Related]
6. A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus.
Anguiano-Zarate SS; Matchett WE; Nehete PN; Sastry JK; Marzi A; Barry MA
J Infect Dis; 2018 Nov; 218(12):1883-1889. PubMed ID: 29982595
[TBL] [Abstract][Full Text] [Related]
7. Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans.
Vu H; Shulenin S; Grolla A; Audet J; He S; Kobinger G; Unfer RC; Warfield KL; Aman MJ; Holtsberg FW
Antiviral Res; 2016 Feb; 126():55-61. PubMed ID: 26681387
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine Expressing Glycoprotein from the 2014 Epidemic Strain in Mice.
Wang L; Liu J; Kong Y; Hou L; Li Y
Hum Gene Ther; 2018 Jan; 29(1):87-95. PubMed ID: 28795602
[TBL] [Abstract][Full Text] [Related]
9. Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.
Aviles J; Bello A; Wong G; Fausther-Bovendo H; Qiu X; Kobinger G
J Infect Dis; 2015 Oct; 212 Suppl 2():S389-97. PubMed ID: 26038398
[TBL] [Abstract][Full Text] [Related]
10. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.
Marzi A; Ebihara H; Callison J; Groseth A; Williams KJ; Geisbert TW; Feldmann H
J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1066-74. PubMed ID: 21987743
[TBL] [Abstract][Full Text] [Related]
11. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G
Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779
[TBL] [Abstract][Full Text] [Related]
12. An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques.
Feng Y; Li C; Hu P; Wang Q; Zheng X; Zhao Y; Shi Y; Yang S; Yi C; Feng Y; Wu C; Qu L; Xu W; Li Y; Sun C; Gao FG; Xia X; Feng L; Chen L
Emerg Microbes Infect; 2018 Jun; 7(1):101. PubMed ID: 29872043
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of propagation-restricted vesicular stomatitis virus encoding Ebola virus glycoprotein in guinea pigs.
Locher S; Schweneker M; Hausmann J; Zimmer G
J Gen Virol; 2018 Jul; 99(7):866-879. PubMed ID: 29869979
[TBL] [Abstract][Full Text] [Related]
14. Recombinant subunit vaccines protect guinea pigs from lethal Ebola virus challenge.
Lehrer AT; Wong TS; Lieberman MM; Johns L; Medina L; Feldmann F; Feldmann H; Marzi A
Vaccine; 2019 Nov; 37(47):6942-6950. PubMed ID: 31324500
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice.
Li W; Ye L; Carrion R; Mohan GS; Nunneley J; Staples H; Ticer A; Patterson JL; Compans RW; Yang C
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S398-403. PubMed ID: 25877553
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
Zhu FC; Wurie AH; Hou LH; Liang Q; Li YH; Russell JB; Wu SP; Li JX; Hu YM; Guo Q; Xu WB; Wurie AR; Wang WJ; Zhang Z; Yin WJ; Ghazzawi M; Zhang X; Duan L; Wang JZ; Chen W
Lancet; 2017 Feb; 389(10069):621-628. PubMed ID: 28017399
[TBL] [Abstract][Full Text] [Related]
17. A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses.
Wu F; Zhang S; Zhang Y; Mo R; Yan F; Wang H; Wong G; Chi H; Wang T; Feng N; Gao Y; Xia X; Zhao Y; Yang S
Viruses; 2020 Jan; 12(1):. PubMed ID: 31947873
[TBL] [Abstract][Full Text] [Related]
18. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain.
Marzi A; Robertson SJ; Haddock E; Feldmann F; Hanley PW; Scott DP; Strong JE; Kobinger G; Best SM; Feldmann H
Science; 2015 Aug; 349(6249):739-42. PubMed ID: 26249231
[TBL] [Abstract][Full Text] [Related]
19. A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates.
Pyankov OV; Bodnev SA; Pyankova OG; Solodkyi VV; Pyankov SA; Setoh YX; Volchkova VA; Suhrbier A; Volchkov VV; Agafonov AA; Khromykh AA
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S368-71. PubMed ID: 25732811
[TBL] [Abstract][Full Text] [Related]
20. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
Matassov D; Marzi A; Latham T; Xu R; Ota-Setlik A; Feldmann F; Geisbert JB; Mire CE; Hamm S; Nowak B; Egan MA; Geisbert TW; Eldridge JH; Feldmann H; Clarke DK
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S443-51. PubMed ID: 26109675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
